Full Press Release Details
AC Immune First Quarter 2026 Financial and Corporate Updates
Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ:
ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial
and corporate updates for the quarter ended March 31, 2026.
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "The
progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation
inhibitor small molecules, respectively. These have the potential to change the way we target the proteinopathies that drive Alzheimer's
and other neurodegenerative diseases (NDDs). This is further exemplified by the presentation of the interim results for ACI-7104 at AD/PD
2026 showing that our active immunotherapy targeting a-synuclein (a-syn) has the potential to modify disease pathology in Parkinson's
disease (PD). We also advanced our NLRP3 inhibitor ACI-19764 into clinical development, further demonstrating the power of AC Immune's
technology to target the key pathways that contribute to neurodegeneration.
"We are now moving towards multiple value inflection points during
2026. These include Phase 2 data readouts on our active immunotherapies ACI-7104 and ACI-24, and initial results from the Phase 1 trial
of ACI-19764 also anticipated this year."
Q1 2026 and Subsequent Highlights:
ACI-24 anti-Abeta active immunotherapy
Morphomer-Tau small molecule program
ACI-7104, anti-a-syn active immunotherapy
NLRP3 inhibitor, ACI-19764, small molecule program
ACI-35 (JNJ-2056) anti-pTau active immunotherapy
AC Immune AD/PDTM 2026 symposium
Anticipated 2026 Milestones
| Program | Milestone | Expected in |
| ACI-7104.056 anti-a-syn active immunotherapy | Final data from Part 1 of the Phase 2 VacSYn trial in PD | H2 2026 |
| ACI-24.060 anti-Abeta active immunotherapy | Interim results from ABATE Phase 2 trial after reaching 12-month treatment timepoint in the AD3 cohort | H1 2026 |
| ACI-19764 NLRP3 inhibitor | Results from Phase 1 trial in healthy volunteers | H2 2026 |
| Morphomer-Tau aggregation inhibitors | Initiation of IND-enabling studies | H1 2026 |
| Morphomer a-syn aggregation inhibitor | Lead declaration | H1 2026 |
Analysis of Financial Statements for the Quarter Ended March 31,
CHF 55.6 million in short-term financial assets. The Company's
cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments.
AC Immune SA is a clinical-stage biopharmaceutical company and a global
leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan
indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen
and Morphomer , fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and
diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic
partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs
and >$4.5 billion in potential milestone payments plus royalties.
SupraAntigen is a registered trademark of AC Immune
SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer is a registered trademark of AC Immune
SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein
is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial
or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expects," "plans,"
"anticipates," "believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's
current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business
decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under
the captions "Item 3. Key Information - Risk Factors" and "Item 5. Operating and Financial Review and Prospects"
in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements
speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future
developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety
by this cautionary statement.
Condensed Consolidated Balance Sheets (Unaudited)
| As of | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Non-current assets | ||||||||
| Property, plant and equipment | 2,057 | 1,989 | ||||||
| Right-of-use assets | 4,310 | 4,540 | ||||||
| Intangible asset | 50,416 | 50,416 | ||||||
| Long-term financial assets | 585 | 584 | ||||||
| Total non-current assets | 57,368 | 57,529 | ||||||
| Current assets | ||||||||
| Prepaid expenses | 3,744 | 3,972 | ||||||
| Accrued income | 230 | 360 | ||||||
| Other current receivables | 1,282 | 978 | ||||||
| Short-term financial assets | 55,628 | 64,617 | ||||||
| Cash and cash equivalents | 19,169 | 26,795 | ||||||
| Total current assets | 80,053 | 96,722 | ||||||
| Total assets | 137,421 | 154,251 | ||||||
| Shareholders' equity and liabilities | ||||||||
| Shareholders' equity | ||||||||
| Share capital | 2,257 | 2,253 | ||||||
| Share premium | 482,345 | 481,863 | ||||||
| Treasury shares | (218 | ) | (218 | ) | ||||
| Currency translation differences | 7 | 7 | ||||||
| Accumulated losses | (452,857 | ) | (439,021 | ) | ||||
| Total shareholders' equity | 31,534 | 44,884 | ||||||
| Non-current liabilities | ||||||||
| Long-term deferred contract revenue | 1,292 | 2,339 | ||||||
| Long-term lease liabilities | 3,479 | 3,689 | ||||||
| Net employee defined benefit liabilities | 8,868 | 8,646 | ||||||
| Total non-current liabilities | 13,639 | 14,674 | ||||||
| Current liabilities | ||||||||
| Trade and other payables | 1,319 | 2,068 | ||||||
| Accrued expenses | 6,469 | 8,067 | ||||||
| Short-term deferred contract revenue | 83,635 | 83,706 | ||||||
| Short-term lease liabilities | 825 | 852 | ||||||
| Total current liabilities | 92,248 | 94,693 | ||||||
| Total liabilities | 105,887 | 109,367 | ||||||
| Total shareholders' equity and liabilities | 137,421 | 154,251 |
Condensed Consolidated Statements of Income/(Loss)
(In CHF thousands, except for per-share data)
| For the Three Months | ||||||||
| Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | ||||||||
| Contract revenue | 1,119 | 990 | ||||||
| Total revenue | 1,119 | 990 | ||||||
| Operating expenses | ||||||||
| Research & development expenses | (11,744 | ) | (15,916 | ) | ||||
| General & administrative expenses | (4,174 | ) | (4,443 | ) | ||||
| Other operating income/(expense), net | 11 | (1 | ) | |||||
| Total operating expenses | (15,907 | ) | (20,360 | ) | ||||
| Operating loss | (14,788 | ) | (19,370 | ) | ||||
| Financial income | 228 | 687 | ||||||
| Financial expense | (65 | ) | (54 | ) | ||||
| Exchange differences | (176 | ) | (292 | ) | ||||
| Finance result, net | (13 | ) | 341 | |||||
| Loss before tax | (14,801 | ) | (19,029 | ) | ||||
| Income tax expense | - | - | ||||||
| Loss for the period | (14,801 | ) | (19,029 | ) | ||||
| Loss per share: | ||||||||
| Basic and diluted loss per share for the period attributable to equity holders | (0.15 | ) | (0.19 | ) |
Condensed Consolidated Statements of Comprehensive
Income/(Loss) (Unaudited)
| For the Three Months | ||||||||
| ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Loss for the period | (14,801 | ) | (19,029 | ) | ||||
| Items that will be reclassified to income or loss in subsequent periods (net of tax): | ||||||||
| Currency translation differences | 0 | 4 | ||||||
| Other comprehensive income/(loss) | 0 | 4 | ||||||
| Total comprehensive loss, net of tax | (14,801 | ) | (19,025 | ) |